<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://wiki.jackslab.org/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="zh-cn">
		<id>http://wiki.jackslab.org/index.php?action=history&amp;feed=atom&amp;title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4</id>
		<title>静脉注射脂质体包封的胞壁酰三肽治疗狗骨肉瘤 - 版本历史</title>
		<link rel="self" type="application/atom+xml" href="http://wiki.jackslab.org/index.php?action=history&amp;feed=atom&amp;title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4"/>
		<link rel="alternate" type="text/html" href="http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;action=history"/>
		<updated>2026-09-11T05:50:45Z</updated>
		<subtitle>本wiki的该页面的版本历史</subtitle>
		<generator>MediaWiki 1.19.2</generator>

	<entry>
		<id>http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16875&amp;oldid=prev</id>
		<title>Comcat：/* Introduction */</title>
		<link rel="alternate" type="text/html" href="http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16875&amp;oldid=prev"/>
				<updated>2024-06-28T08:05:10Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Introduction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class='diff diff-contentalign-left'&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
			&lt;tr valign='top'&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←上一版本&lt;/td&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;2024年6月28日 (五) 08:05的版本&lt;/td&gt;
			&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;第12行：&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;第12行：&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Introduction ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Introduction ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;== Reference ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* 2000: [[犬血管肉瘤的治疗：2000 年及以后]]兽医内科杂志 [https://pubmed.ncbi.nlm.nih.gov/11012108/ Treatment of canine hemangiosarcoma: 2000 and beyond. Journal of Veterinary Internal Medicine 2000]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* 2010: [[狗的胸腔镜次全心包切除术和右心房肿块切除术]] [https://pubmed.ncbi.nlm.nih.gov/20807133/ Thoracoscopic subtotal pericardiectomy and right atrial mass resection in a dog]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* 2013: [[狗狗原发性心脏血管肉瘤的流行病学、临床和病理特征：51例的回顾]]。兽医学杂志 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942993/ Epidemiological, clinical and pathological features of primary cardiac hemangiosarcoma in dogs: a review of 51 cases.] &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* 2014: [http://wiki.jackslab.org/2014.Doxorubicin.HSA 阿霉素化疗治疗狗的推定性心脏血管肉瘤] [https://pubmed.ncbi.nlm.nih.gov/25524594 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs] &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* 2014: [[基于多柔比星的化疗对右心房肿块和心包积液狗的回顾性评估]] [https://pubmed.ncbi.nlm.nih.gov/24697499/ A retrospective evaluation of doxorubicin-based chemotherapy for dogs with right atrial masses and pericardial effusion]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* 2017: [http://wiki.jackslab.org/2017.HSA.doxorubicin.AC.vs.ADTIC 多柔比星-环磷酰胺与多柔比星-达卡巴嗪辅助治疗犬血管肉瘤的比较] [https://pubmed.ncbi.nlm.nih.gov/25623994/ Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for HSA] &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* 2018: [[犬内脏血管肉瘤单独手术治疗或手术加多柔比星治疗：37例（2005-2014年）]] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091137/ Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005–2014)]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* [https://todaysveterinarypractice.com/nutrition/nutritional-management-of-veterinary-patients-with-neoplasia/ Nutritional Management of Patients with Neoplasia] [[小动物肿瘤患者的营养管理]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;* [[狗狗心包积液]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Comcat</name></author>	</entry>

	<entry>
		<id>http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16872&amp;oldid=prev</id>
		<title>2024年6月28日 (五) 07:58 Comcat</title>
		<link rel="alternate" type="text/html" href="http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16872&amp;oldid=prev"/>
				<updated>2024-06-28T07:58:15Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class='diff diff-contentalign-left'&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
			&lt;tr valign='top'&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←上一版本&lt;/td&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;2024年6月28日 (五) 07:58的版本&lt;/td&gt;
			&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;第5行：&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;第5行：&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Abstract ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Abstract ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;犬骨肉瘤 (osteosarcoma) &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;是狗的一种自发性恶性肿瘤，其特征是在诊断时微转移至肺和肺外组织。标准治疗包括截肢，但中位生存时间为 &lt;/del&gt;3-4 个月，因转移而死亡。进行了一项随机双盲试验，以评估脂质体封装的胞壁酰三肽-磷脂酰乙醇胺（脂质体/MTP-PE）作为治疗因骨肉瘤而截肢的狗的转移。14 只狗接受脂质体/MTP-PE 治疗，13 只狗接受空脂质体治疗。用脂质体/MTP-PE 治疗的狗的中位生存时间为 222 天，而用空脂质体治疗的狗的中位生存时间为 77 天（P 小于 0.002）。在脂质体/MTP-PE治疗组中，仍有四只狗在手术后 1 年以上存活且无转移。治疗耐受性良好。除了注射后 2-6 小时体温轻度升高（1-2 摄氏度）外，没有观察到显着的毒性作用。&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;犬骨肉瘤 (osteosarcoma) &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;是狗的一种自发性恶性肿瘤，其特征是在'''诊断时微转移至肺和肺外组织'''。标准治疗包括'''截肢'''，但中位生存时间为 &lt;/ins&gt;3-4 个月，因转移而死亡。进行了一项随机双盲试验，以评估脂质体封装的胞壁酰三肽-磷脂酰乙醇胺（脂质体/MTP-PE）作为治疗因骨肉瘤而截肢的狗的转移。14 只狗接受脂质体/MTP-PE 治疗，13 只狗接受空脂质体治疗。用脂质体/MTP-PE 治疗的狗的中位生存时间为 222 天，而用空脂质体治疗的狗的中位生存时间为 77 天（P 小于 0.002）。在脂质体/MTP-PE治疗组中，仍有四只狗在手术后 1 年以上存活且无转移。治疗耐受性良好。除了注射后 2-6 小时体温轻度升高（1-2 摄氏度）外，没有观察到显着的毒性作用。&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Canine osteosarcoma is a spontaneous malignancy in dogs, characterized by micrometastasis to pulmonary and extrapulmonary tissues at the time of diagnosis. Standard treatment involves amputation of the affected leg, but median survival time is 3-4 months with death due to metastasis. A randomized double-blind trial was conducted to evaluate liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (liposome/MTP-PE) as a treatment for metastasis in dogs undergoing amputation for osteosarcoma. Fourteen dogs were treated with liposome/MTP-PE, and 13 were treated with empty liposomes. Median survival time was 222 days for dogs treated with liposome/MTP-PE, compared to 77 days for dogs treated with empty liposomes (P less than .002). In the liposome/MTP-PE-treated group there were still four dogs alive and free of metastasis at greater than 1 year post surgery. Treatment was well tolerated; no significant toxic effects were noted except for mild elevations in body temperature (1-2 degrees C) for 2-6 hours post injection.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Canine osteosarcoma is a spontaneous malignancy in dogs, characterized by micrometastasis to pulmonary and extrapulmonary tissues at the time of diagnosis. Standard treatment involves amputation of the affected leg, but median survival time is 3-4 months with death due to metastasis. A randomized double-blind trial was conducted to evaluate liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (liposome/MTP-PE) as a treatment for metastasis in dogs undergoing amputation for osteosarcoma. Fourteen dogs were treated with liposome/MTP-PE, and 13 were treated with empty liposomes. Median survival time was 222 days for dogs treated with liposome/MTP-PE, compared to 77 days for dogs treated with empty liposomes (P less than .002). In the liposome/MTP-PE-treated group there were still four dogs alive and free of metastasis at greater than 1 year post surgery. Treatment was well tolerated; no significant toxic effects were noted except for mild elevations in body temperature (1-2 degrees C) for 2-6 hours post injection.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Comcat</name></author>	</entry>

	<entry>
		<id>http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16871&amp;oldid=prev</id>
		<title>2024年6月28日 (五) 07:57 Comcat</title>
		<link rel="alternate" type="text/html" href="http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16871&amp;oldid=prev"/>
				<updated>2024-06-28T07:57:53Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class='diff diff-contentalign-left'&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
			&lt;tr valign='top'&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←上一版本&lt;/td&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;2024年6月28日 (五) 07:57的版本&lt;/td&gt;
			&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;第5行：&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;第5行：&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Abstract ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Abstract ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;犬骨肉瘤是狗的一种自发性恶性肿瘤，其特征是在诊断时微转移至肺和肺外组织。标准治疗包括截肢，但中位生存时间为 &lt;/del&gt;3-4 个月，因转移而死亡。进行了一项随机双盲试验，以评估脂质体封装的胞壁酰三肽-磷脂酰乙醇胺（脂质体/MTP-PE）作为治疗因骨肉瘤而截肢的狗的转移。14 只狗接受脂质体/MTP-PE 治疗，13 只狗接受空脂质体治疗。用脂质体/MTP-PE 治疗的狗的中位生存时间为 222 天，而用空脂质体治疗的狗的中位生存时间为 77 天（P 小于 0.002）。在脂质体/MTP-PE治疗组中，仍有四只狗在手术后 1 年以上存活且无转移。治疗耐受性良好。除了注射后 2-6 小时体温轻度升高（1-2 摄氏度）外，没有观察到显着的毒性作用。&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;犬骨肉瘤 (osteosarcoma) 是狗的一种自发性恶性肿瘤，其特征是在诊断时微转移至肺和肺外组织。标准治疗包括截肢，但中位生存时间为 &lt;/ins&gt;3-4 个月，因转移而死亡。进行了一项随机双盲试验，以评估脂质体封装的胞壁酰三肽-磷脂酰乙醇胺（脂质体/MTP-PE）作为治疗因骨肉瘤而截肢的狗的转移。14 只狗接受脂质体/MTP-PE 治疗，13 只狗接受空脂质体治疗。用脂质体/MTP-PE 治疗的狗的中位生存时间为 222 天，而用空脂质体治疗的狗的中位生存时间为 77 天（P 小于 0.002）。在脂质体/MTP-PE治疗组中，仍有四只狗在手术后 1 年以上存活且无转移。治疗耐受性良好。除了注射后 2-6 小时体温轻度升高（1-2 摄氏度）外，没有观察到显着的毒性作用。&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Canine osteosarcoma is a spontaneous malignancy in dogs, characterized by micrometastasis to pulmonary and extrapulmonary tissues at the time of diagnosis. Standard treatment involves amputation of the affected leg, but median survival time is 3-4 months with death due to metastasis. A randomized double-blind trial was conducted to evaluate liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (liposome/MTP-PE) as a treatment for metastasis in dogs undergoing amputation for osteosarcoma. Fourteen dogs were treated with liposome/MTP-PE, and 13 were treated with empty liposomes. Median survival time was 222 days for dogs treated with liposome/MTP-PE, compared to 77 days for dogs treated with empty liposomes (P less than .002). In the liposome/MTP-PE-treated group there were still four dogs alive and free of metastasis at greater than 1 year post surgery. Treatment was well tolerated; no significant toxic effects were noted except for mild elevations in body temperature (1-2 degrees C) for 2-6 hours post injection.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Canine osteosarcoma is a spontaneous malignancy in dogs, characterized by micrometastasis to pulmonary and extrapulmonary tissues at the time of diagnosis. Standard treatment involves amputation of the affected leg, but median survival time is 3-4 months with death due to metastasis. A randomized double-blind trial was conducted to evaluate liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (liposome/MTP-PE) as a treatment for metastasis in dogs undergoing amputation for osteosarcoma. Fourteen dogs were treated with liposome/MTP-PE, and 13 were treated with empty liposomes. Median survival time was 222 days for dogs treated with liposome/MTP-PE, compared to 77 days for dogs treated with empty liposomes (P less than .002). In the liposome/MTP-PE-treated group there were still four dogs alive and free of metastasis at greater than 1 year post surgery. Treatment was well tolerated; no significant toxic effects were noted except for mild elevations in body temperature (1-2 degrees C) for 2-6 hours post injection.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Comcat</name></author>	</entry>

	<entry>
		<id>http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16870&amp;oldid=prev</id>
		<title>Comcat：/* Abstract */</title>
		<link rel="alternate" type="text/html" href="http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16870&amp;oldid=prev"/>
				<updated>2024-06-28T07:57:33Z</updated>
		
		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Abstract&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class='diff diff-contentalign-left'&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
			&lt;tr valign='top'&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←上一版本&lt;/td&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;2024年6月28日 (五) 07:57的版本&lt;/td&gt;
			&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;第6行：&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;第6行：&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;犬骨肉瘤是狗的一种自发性恶性肿瘤，其特征是在诊断时微转移至肺和肺外组织。标准治疗包括截肢，但中位生存时间为 3-4 个月，因转移而死亡。进行了一项随机双盲试验，以评估脂质体封装的胞壁酰三肽-磷脂酰乙醇胺（脂质体/MTP-PE）作为治疗因骨肉瘤而截肢的狗的转移。14 只狗接受脂质体/MTP-PE 治疗，13 只狗接受空脂质体治疗。用脂质体/MTP-PE 治疗的狗的中位生存时间为 222 天，而用空脂质体治疗的狗的中位生存时间为 77 天（P 小于 0.002）。在脂质体/MTP-PE治疗组中，仍有四只狗在手术后 1 年以上存活且无转移。治疗耐受性良好。除了注射后 2-6 小时体温轻度升高（1-2 摄氏度）外，没有观察到显着的毒性作用。&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;犬骨肉瘤是狗的一种自发性恶性肿瘤，其特征是在诊断时微转移至肺和肺外组织。标准治疗包括截肢，但中位生存时间为 3-4 个月，因转移而死亡。进行了一项随机双盲试验，以评估脂质体封装的胞壁酰三肽-磷脂酰乙醇胺（脂质体/MTP-PE）作为治疗因骨肉瘤而截肢的狗的转移。14 只狗接受脂质体/MTP-PE 治疗，13 只狗接受空脂质体治疗。用脂质体/MTP-PE 治疗的狗的中位生存时间为 222 天，而用空脂质体治疗的狗的中位生存时间为 77 天（P 小于 0.002）。在脂质体/MTP-PE治疗组中，仍有四只狗在手术后 1 年以上存活且无转移。治疗耐受性良好。除了注射后 2-6 小时体温轻度升高（1-2 摄氏度）外，没有观察到显着的毒性作用。&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Canine osteosarcoma is a spontaneous malignancy in dogs, characterized by micrometastasis to pulmonary and extrapulmonary tissues at the time of diagnosis. Standard treatment involves amputation of the affected leg, but median survival time is 3-4 months with death due to metastasis. A randomized double-blind trial was conducted to evaluate liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (liposome/MTP-PE) as a treatment for metastasis in dogs undergoing amputation for osteosarcoma. Fourteen dogs were treated with liposome/MTP-PE, and 13 were treated with empty liposomes. Median survival time was 222 days for dogs treated with liposome/MTP-PE, compared to 77 days for dogs treated with empty liposomes (P less than .002). In the liposome/MTP-PE-treated group there were still four dogs alive and free of metastasis at greater than 1 year post surgery. Treatment was well tolerated; no significant toxic effects were noted except for mild elevations in body temperature (1-2 degrees C) for 2-6 hours post injection.&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Comcat</name></author>	</entry>

	<entry>
		<id>http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16869&amp;oldid=prev</id>
		<title>Comcat：以“原文：https://pubmed.ncbi.nlm.nih.gov/2733037/  Published: 1989  == Abstract ==  犬骨肉瘤是狗的一种自发性恶性肿瘤，其特征是在诊断时微转...”为内容创建页面</title>
		<link rel="alternate" type="text/html" href="http://wiki.jackslab.org/index.php?title=%E9%9D%99%E8%84%89%E6%B3%A8%E5%B0%84%E8%84%82%E8%B4%A8%E4%BD%93%E5%8C%85%E5%B0%81%E7%9A%84%E8%83%9E%E5%A3%81%E9%85%B0%E4%B8%89%E8%82%BD%E6%B2%BB%E7%96%97%E7%8B%97%E9%AA%A8%E8%82%89%E7%98%A4&amp;diff=16869&amp;oldid=prev"/>
				<updated>2024-06-28T07:57:01Z</updated>
		
		<summary type="html">&lt;p&gt;以“原文：https://pubmed.ncbi.nlm.nih.gov/2733037/  Published: 1989  == Abstract ==  犬骨肉瘤是狗的一种自发性恶性肿瘤，其特征是在诊断时微转...”为内容创建页面&lt;/p&gt;
&lt;p&gt;&lt;b&gt;新页面&lt;/b&gt;&lt;/p&gt;&lt;div&gt;原文：https://pubmed.ncbi.nlm.nih.gov/2733037/&lt;br /&gt;
&lt;br /&gt;
Published: 1989&lt;br /&gt;
&lt;br /&gt;
== Abstract ==&lt;br /&gt;
&lt;br /&gt;
犬骨肉瘤是狗的一种自发性恶性肿瘤，其特征是在诊断时微转移至肺和肺外组织。标准治疗包括截肢，但中位生存时间为 3-4 个月，因转移而死亡。进行了一项随机双盲试验，以评估脂质体封装的胞壁酰三肽-磷脂酰乙醇胺（脂质体/MTP-PE）作为治疗因骨肉瘤而截肢的狗的转移。14 只狗接受脂质体/MTP-PE 治疗，13 只狗接受空脂质体治疗。用脂质体/MTP-PE 治疗的狗的中位生存时间为 222 天，而用空脂质体治疗的狗的中位生存时间为 77 天（P 小于 0.002）。在脂质体/MTP-PE治疗组中，仍有四只狗在手术后 1 年以上存活且无转移。治疗耐受性良好。除了注射后 2-6 小时体温轻度升高（1-2 摄氏度）外，没有观察到显着的毒性作用。&lt;br /&gt;
&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Introduction ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;/div&gt;</summary>
		<author><name>Comcat</name></author>	</entry>

	</feed>